Search results
Added:
11 months ago
ESC-HFA 23 - Dr Jawad Haider Butt (Copenhagen University Hospital, DK) outlines the findings of a patient-level meta-analysis of the DAPA-HF and DELIVER trials, which studied the safety and effectiveness of dapagliflozin on patients with both peripheral arterial disease and heart failure. These trials covered the spectrum of patients with heart failure.
The findings of this meta-analysis suggest…
View more
Added:
3 years ago
Dr Alice M Jackson (University of Glasgow, Glasgow, UK) discusses the findings from a DAPA-HF sub-analysis. The analysis focused on dapaglifozin and its diuretic use in patients with heart failure and reduced ejection fraction (HFrEF).
Questions:
1.Can you briefly summarise the DAPA-HF trial?
2.What was the rationale of this sub-analysis and what were its aims?
3.What was the design of the…
View more
Added:
5 months ago
AHA 2023 — Investigator, Prof Stefan James, Prof Jonas Oldgren (Uppsala University, SE) and Late-breaker host, Dr Harriette Van Spall (McMaster University, CA) discuss the findings of the DAPA-MI trial (NCT04564742).This multicenter, parallel-group, registry-based, randomized, double-blind and placebo-controlled phase 3 trial (AstraZeneca) investigated the effect of dapagliflozin 10 mg vs placebo…
View more
Added:
11 months ago
ESC-HFA 23 –Dr Ross Campbell (University of Glasgow, UK)joins us onsite to discuss the findings of the DAPA-RESIST Trial, which aimed to assess the affect of dapagliflozin as compared to metolazone in heart failure patients with diuretic resistance (NCT04860011).
In this phase 3 trial, investigators studied whether SGLT2i led to greater diuresis in this patient group, as to the standard practice…
View more
Added:
1 year ago
In this short interview, Dr Scott Solomon (Brigham And Women's Hospital & Harvard Medical School, Boston, MA, US) discusses the design and baseline of the DELIVER trial.
This trial was designed to evaluate the effects of the dapagliflozin on cardiovascular death, heart failure (HF) hospitalization, or urgent HF visits in patients with HF with mildly reduced and preserved left ventricular ejection…
View more
Added:
11 months ago
ESC-HFA 2023 - Dr Ankeet Bhatt (Kaiser Permanante San Francisco Medical Center, US) joins us onsite to discuss a study that looked into Kansas City Cardiomyopathy Questionnaire (KCCQ) scores in patients with varying ejection fractions, that were enrolled in the DELIVER and DAPA-HF trials.
This study used pooled, patient-level data from the DAPA-HF and DELIVER studies, aiming to examine the…
View more
Added:
1 year ago
HFA 2023: Late-Breaking Science Video Collection
Video Series
Added:
3 years ago
In this series, Mikhail Kosiborod and Hertzel Gerstein discuss the effects of Covid-19 and metabolic disease, early treatment with metabolic therapies and the Phase III DARE-19 Trial looking at dapagliflozin in Covid-19 patients.
Recorded remotely from Hamilton and Kansas City, 2020.
View more
Added:
11 months ago
ESC-HFA 2023 — Prof Domingo Pascual Figal (Hospital Clinico Universitario Virgen de la Arrixaca, SP) discusses the DAPA MODA study (NCT04707352).
The study aimed to assess the effects of dapagliflozin on cardiac remodeling parameters, particularly LA geometry and function, and biomarkers reflecting pathophysiological pathways. Findings from ESC Heart Failure 2023 revealed that dapagliflozin…
View more
